Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 20;146(6):438–449. doi: 10.1161/CIRCULATIONAHA.121.058910

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Risk of prespecified outcomes for patients experiencing a >10% decline in eGFR between baseline and day 14 compared with patients not experiencing a >10% decline in eGFR within each randomized treatment group. Follow-up is for outcomes occurring after 14 days (landmark analysis). Models are stratified by diabetes status and adjusted for baseline estimated glomerular filtration rate (eGFR) and history of heart failure (HF) hospitalization (HF hospitalization for each outcome apart from all-cause mortality). Analysis for all patients includes adjustment for randomized treatment. For example, between day 14 and the end of the study, the risk of the primary outcome (cardiovascular [CV] death or worsening HF) was 45% higher in patients randomized to placebo who experienced a >10% decline in eGFR between baseline and day 14 compared with placebo-treated patients who did not experience this decline. Conversely, the risk of the primary outcome was 27% lower among patients randomized to dapagliflozin who experienced a >10% decline in eGFR compared with dapagliflozin-treated patients who did not experience a >10% decline in eGFR between day 0 and 14. HR indicates hazard ratio; and RR, rate ratio.